CIM Investment Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$519K Sell
2,830
-14
-0.5% -$2.58K 0.14% 127
2025
Q4
$501K Hold
2,844
0.13% 128
2025
Q3
$398K Sell
2,844
-2,920
-51% -$395K 0.11% 148
2025
Q2
$803K Buy
5,764
+2,877
+100% +$358K 0.15% 127
2025
Q1
$395K Sell
2,887
-3
-0.1% -$429 0.09% 138
2024
Q4
$442K Buy
2,890
+13
+0.5% +$2.19K 0.13% 130
2024
Q3
$558K Sell
2,877
-52
-2% -$10.9K 0.16% 111
2024
Q2
$679K Sell
2,929
-17
-0.6% -$3.69K 0.21% 93
2024
Q1
$635K Hold
2,946
0.19% 109
2023
Q4
$762K Sell
2,946
-130
-4% -$31.9K 0.25% 81
2023
Q3
$791K Sell
3,076
-72
-2% -$19.3K 0.29% 74
2023
Q2
$897K Buy
3,148
+22
+0.7% +$6.55K 0.31% 67
2023
Q1
$869K Buy
3,126
+147
+5% +$40.7K 0.32% 63
2022
Q4
$825K Sell
2,979
-1,612
-35% -$455K 0.32% 58
2022
Q3
$1.23M Hold
4,591
0.54% 27
2022
Q2
$936K Sell
4,591
-24
-0.5% -$4.91K 0.39% 44
2022
Q1
$972K Sell
4,615
-5
-0.1% -$1.09K 0.33% 64
2021
Q4
$1.11M Buy
4,620
+611
+15% +$157K 0.33% 49
2021
Q3
$1.14M Buy
4,009
+1,286
+47% +$421K 0.36% 48
2021
Q2
$943K Sell
2,723
-62
-2% -$18.8K 0.29% 68
2021
Q1
$779K Sell
2,785
-2,993
-52% -$807K 0.25% 76
2020
Q4
$1.42M Buy
5,778
+4,372
+311% +$1.13M 0.46% 36
2020
Q3
$399K Sell
1,406
-13
-0.9% -$3.63K 0.15% 130
2020
Q2
$380K Hold
1,419
0.15% 132
2020
Q1
$449K Buy
1,419
+43
+3% +$13K 0.22% 100
2019
Q4
$408K Hold
1,376
0.16% 134
2019
Q3
$320K Sell
1,376
-140
-9% -$32.6K 0.12% 212
2019
Q2
$355K Buy
1,516
+65
+4% +$15K 0.13% 195
2019
Q1
$343K Sell
1,451
-1,461
-50% -$460K 0.13% 207
2018
Q4
$876K Buy
2,912
+1,461
+101% +$466K 0.38% 40
2018
Q3
$513K Hold
1,451
0.18% 146
2018
Q2
$421K Sell
1,451
-37
-2% -$10.4K 0.15% 196
2018
Q1
$407K Sell
1,488
-34
-2% -$10.6K 0.14% 207
2017
Q4
$485K Sell
1,522
-22
-1% -$7.06K 0.17% 176
2017
Q3
$483K Sell
1,544
-1,767
-53% -$523K 0.18% 167
2017
Q2
$898K Sell
3,311
-47
-1% -$12.4K 0.32% 66
2017
Q1
$918K Sell
3,358
-304
-8% -$86K 0.32% 69
2016
Q4
$1.04M Buy
3,662
+54
+1% +$16K 0.38% 49
2016
Q3
$1.13M Sell
3,608
-260
-7% -$77K 0.43% 40
2016
Q2
$935K Buy
3,868
+1,717
+80% +$453K 0.39% 63
2016
Q1
$560K Sell
2,151
-215
-9% -$56.8K 0.24% 122
2015
Q4
$725K Hold
2,366
0.33% 108
2015
Q3
$690K Buy
2,366
+62
+3% +$20.5K 0.33% 113
2015
Q2
$931K Sell
2,304
-13
-0.6% -$5.22K 0.41% 84
2015
Q1
$978K Hold
2,317
0.42% 83
2014
Q4
$787K Sell
2,317
-2,181
-48% -$706K 0.36% 104
2014
Q3
$1.49M Sell
4,498
-276
-6% -$91K 0.76% 29
2014
Q2
$1.5M Sell
4,774
-138
-3% -$41.5K 0.76% 30
2014
Q1
$1.5M Sell
4,912
-149
-3% -$47.3K 0.69% 30
2013
Q4
$1.42M Buy
5,061
+250
+5% +$64.7K 0.72% 41
2013
Q3
$1.16M Hold
4,811
0.69% 50
2013
Q2
$1.03M Buy
+4,811
New +$1.03M 0.61% 57

Other funds holding BIIB

CIM Investment Management's BIIB Position: Q1 2026 in Review

CIM Investment Management reduced its Biogen (BIIB) stake by 0.49% in Q1 2026, selling an estimated $2.58K and leaving 2,830 shares worth $519K. The position accounts for 0.14% of the portfolio, ranked #127.

CIM Investment Management first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.5M in Q2 2014. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • CIM Investment Management held 2,830 shares of Biogen worth $519K as of Q1 2026.
  • CIM Investment Management sold 14 Biogen shares in Q1 2026, an estimated $2.58K.
  • Biogen made up 0.14% of CIM Investment Management's portfolio in Q1 2026, its #127 holding.
  • CIM Investment Management first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • CIM Investment Management's Biogen position peaked at $1.5M in Q2 2014.
  • 1,009 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on CIM Investment Management's 13F filing for Q1 2026, filed 19 May 2026.